B-cell Acute Lymphoblastic Leukemia Clinical Trials

36 recruitingLast updated: May 4, 2026

B-cell Acute Lymphoblastic Leukemia Trials at a Glance

51 actively recruiting trials for b-cell acute lymphoblastic leukemia are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 1 with 26 trials, with the heaviest enrollment activity in Houston, Philadelphia, and Beijing. Lead sponsors running b-cell acute lymphoblastic leukemia studies include The First Affiliated Hospital of Soochow University, Beijing GoBroad Hospital, and AstraZeneca.

Browse b-cell acute lymphoblastic leukemia trials by phase

Treatments under study

About B-cell Acute Lymphoblastic Leukemia Clinical Trials

Looking for clinical trials for B-cell Acute Lymphoblastic Leukemia? There are currently 36 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new B-cell Acute Lymphoblastic Leukemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about B-cell Acute Lymphoblastic Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 51 trials

Recruiting
Phase 1Phase 2

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca163 enrolled80 locationsNCT06137118
Recruiting
Phase 1Phase 2

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaMinimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Amgen104 enrolled4 locationsNCT07134088
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)B-cell Non-Hodgkin's Lymphoma (B-NHL)
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Phase 3

Study of Out of Specification for Tisagenlecleucel

B-cell Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals200 enrolled53 locationsNCT04094311
Recruiting
Phase 1Phase 2

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

B-cell Non Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver45 enrolled1 locationNCT04544592
Recruiting
Phase 1Phase 2

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

B-cell Acute Lymphoblastic Leukemia
Merck Sharp & Dohme LLC90 enrolled67 locationsNCT06395103
Recruiting
Phase 1Phase 2

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1Phase 2

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca83 enrolled26 locationsNCT07109219
Recruiting
Phase 1

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaMantle Cell Lymphoma+5 more
British Columbia Cancer Agency24 enrolled7 locationsNCT06208735
Recruiting
Phase 3

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center130 enrolled3 locationsNCT07223021
Recruiting
Phase 1Phase 2

Co-administration of CART22-65s and huCART19 for B-ALL

B-cell Acute Lymphoblastic LeukemiaB Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD93 enrolled1 locationNCT05674175
Recruiting
Phase 2Phase 3

NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Relapsed/Refractory Non-Hodgkin Lymphoma+2 more
Health Institutes of Turkey40 enrolled4 locationsNCT07502118
Recruiting
Phase 1Phase 2

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+8 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579
Recruiting
Not Applicable

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Acute Lymphoblastic Leukemia, in RelapseB-cell Acute Lymphoblastic LeukemiaRefractory Acute Lymphoid Leukemia
Beijing GoBroad Hospital353 enrolled1 locationNCT06343090
Recruiting
Phase 1

Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

Acute Lymphoblastic Leukemia, in RelapseB-cell Acute Lymphoblastic Leukemia
Beijing GoBroad Hospital48 enrolled1 locationNCT06326008
Recruiting
Not Applicable

CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

Acute Lymphoblastic Leukemia, in RelapseB-cell Acute Lymphoblastic LeukemiaRefractory Acute Lymphoid Leukemia
Beijing GoBroad Hospital213 enrolled1 locationNCT06389305
Recruiting

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

B-cell Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic LeukemiaB-cell Acute Lymphoblastic Leukemia (B-ALL)+4 more
Arkansas Children's Hospital Research Institute300 enrolled2 locationsNCT07422337
Recruiting

Long-term Follow up Local Registry Study of Kymriah in South Korea

B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Novartis Pharmaceuticals500 enrolled16 locationsNCT06785818
Recruiting
Phase 2

A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center60 enrolled1 locationNCT07153796
Recruiting
Phase 1

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

B-cell Acute Lymphoblastic Leukemia
Children's Hospital Medical Center, Cincinnati28 enrolled1 locationNCT06863259